[india-drug] Commission on Intellectual Property Rights, Innovation and

[Sunitha Srinivas <s.srinivas@ru.ac.za>]

Public Health
Sender: owner-india-drug@usa.healthnet.org
Precedence: bulk
Reply-To: india-drug@usa.healthnet.org


(Source: http://www.who.int/mediacentre/releases/2004/pr12/en/
Thanks?.SS)

WHO has announced the membership of the Commission on Intellectual
Property Rights, Innovation and Public Health
---------------------------------------------------------------


12 FEBRUARY 2004 | GENEVA -- The Director-General of WHO, Dr LEE
Jong-wook, today announced the members of the Commission on
Intellectual Property Rights, Innovation and Public Health (CIPIH). The
Commission has been established as a result of a resolution at the 2003
World Health Assembly (WHA56.27).

The resolution called for WHO to establish a time-limited body to
?produce an analysis of intellectual property rights, innovation, and
public health, including the question of appropriate funding and
incentive mechanisms for the creation of new medicines and other
products against diseases that disproportionately affect developing
countries.? The terms of reference and criteria for selection of
Members are contained in a document submitted to WHO?s Executive Board
in January 2004.

The Chairperson of the Commission will be Ms Ruth Dreifuss. She was a
member of the Swiss Government between 1993-2002 and served as
President of the Swiss Confederation in 1999. As Federal Minister of
Interior her responsibilities included, amongst others, public health
and scientific research.

The vice-Chair will be Dr Ragunath Anand Mashelkar, who is the
Director-General of India?s Council of Scientific and Industrial
Research, one of the largest chains of industrial research and
development institutions in the world.

The other eight members of the Commission are (in alphabetical order):

Professor Carlos Correa, a lawyer and economist from Argentina, is
Director of the Centre for Interdisciplinary Studies on Industrial
Property and Economics Law, at the University of Buenos Aires. 
·	Professor Mahmoud Fathalla is a Professor of Obstetrics and
Gynaecology, former Dean of the Medical School at Assiut University,
Egypt, and Chair of the WHO Advisory Committee on Health Research. 
·	Dr Maria Freire is Chief Executive Officer of the Global Alliance for
TB Drug Development, and previously directed the Office of Technology
Transfer at the US National Institutes of Health from 1995 to 2001. 
·	Professor Trevor Jones is Director-General of the Association of the
British Pharmaceutical Industry, and was previously Director of
Research and Development at the Wellcome Foundation Limited. 
·	Mr Tshediso Matona, an economist and trade policy expert, is Deputy
Director-General in South Africa?s Department of Trade and Industry. 
·	Professor Fabio Pammolli is Professor of Economics and Management at
the University of Florence. He is the Director of European
Pharmaceutical Regulation and Innovation Systems at the University of
Siena. 
·	Professor Pakdee Pothisiri, with a background in public health
research, is Senior Deputy Permanent Secretary of Health, Government of
Thailand, and formerly Secretary General of the Thai Food and Drug
Administration. 
·	Professor Hiroko Yamane is Professor of International Economic Law,
Economic Law and European Community Law at the Graduate Institute for
Policy Studies in Tokyo, specialising in trade law, competition and
intellectual property rights. 
The Commissioners are appointed in their individual capacity rather
than as the representative of an institution or government body, and
will have complete independence in carrying out their work. The
Commission will be supported by reference groups for the purposes of
consulting key stakeholders, including the research and
development-based industry and civil society groups. It intends to hold
its first meeting in Geneva in late March. Throughout its work, it will
be supported by a Secretariat within WHO which will help it to organise
the programme of consultations, studies and other activities necessary
for drafting the report. It will submit its report to WHO?s Executive
Board in January 2005
















________________________________________________________________________
Yahoo! India Insurance Special: Be informed on the best policies, services, tools and more. 
Go to: http://in.insurance.yahoo.com/licspecial/index.html

Access Essential Drugs Monitor #32 at http://www.who.int/medicines/mon/mon32.shtml

The INDIA-DRUG discussion group is a partnership between SATELLIFE
(www.healthnet.org), WHO Essential Drugs and Medicines Policy
(www.who.ch), and the Delhi Society for the Promotion of the
Rational Use of Drugs (DSPRUD) in India.

To send a message to india-drug, write to: india-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe india-drug OR unsubscribe india-drug
To contact a person, send a message to: india-drug-help@healthnet.org